SARS-CoV-2 Testing in the Community: Testing Positive Samples with the TaqMan SARS-CoV-2 Mutation Panel To Find...

Area of Science:

• Virology
• Molecular Diagnostics
• Genomics

Background:

• Genome sequencing is crucial for identifying SARS-CoV-2 variants but can face limitations like sequence dropout.
• ThermoFisher Scientific developed genotyping assays to enhance variant identification capabilities.

Purpose of the Study:

• To assess the performance of the ThermoFisher TaqMan mutation panel genotyping assay for detecting SARS-CoV-2 variants.
• To evaluate genotyping as a complement to genome sequencing for clinical applications.

Main Methods:

• A 6-week assessment (April-May 2021) of the ThermoFisher TaqMan genotyping assay.
• Testing against SARS-CoV-2 positive clinical samples and COG-UK sequencing data.
• Assay evaluated for five key mutations of concern.

Main Results:

• Genotyping assays accurately identified specific SARS-CoV-2 mutations.
• The assay demonstrated strong performance when compared to sequencing data.
• Genotyping proved to be a valuable complement to whole-genome sequencing.

Conclusions:

• Genotyping assays are a powerful tool for in-depth mutation identification.
• This technique offers significant potential for clinical health value, enabling faster variant reporting and response.
• Genotyping assays can bridge the gap between testing capacity and sequencing capabilities for real-time variant data.